The only event in Asia bringing global oligonucleotide and peptide leaders together to discuss current strategies and trends to accelerate promising molecules from research to commercialization.
The document advertises the 8th annual Pre-Filled Syringes Americas conference and exhibition taking place from March 31st to April 2nd, 2014 in Iselin, New Jersey. The conference will bring together over 85 key decision makers from leading biotechnology and pharmaceutical companies to discuss developments in pre-filled syringes and injection devices over the course of two days of presentations, panel discussions, and workshops. Attendees will have the opportunity to network with industry leaders, evaluate solutions from exhibitors, and return to their businesses with the information and contacts needed to make decisions for their products.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, services, processes or ideas that are novel to an organization. Innovation can take various forms, including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
The document describes a team developing a technology to stabilize stem cells at room temperature, removing the need for freezing. The team includes Dr. Joanne Hackett, founder and CSO, with experience in regenerative medicine and business development, and Dr. Ryan MacDonald, project manager with a background in stem cell biology. The £100,000 investment would be used to protect intellectual property, undertake further studies, and provide seed funding to secure licensing deals and grants to further develop the technology.
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
Aqua Partners LLC is a global life science consulting firm that has been operating since 1983. They help life science companies access technology, products, partnerships, and capital worldwide. Their team of professionals have expertise in areas such as M&A, strategic partnerships, licensing, clinical development, and venture investing. Aqua Partners provides strategic advisory, valuation, business development, market research, and M&A services to clients in the life science industry globally.
Pitches from the 10 finalist teams selected to compete for the £100,000 Grand Prize of the inaugural OneStart competition in 2013, hosted by the Oxbridge Biotech Roundtable and SR One.
Learn more about this year's competition: http://oxbridgebiotech.com/onestart
SMi Group's 6th annual Pre-Filled Syringes conference & exhibition is already Europe's leading event. This year it will be better than ever. Check out the programme.
The document advertises the 8th annual Pre-Filled Syringes Americas conference and exhibition taking place from March 31st to April 2nd, 2014 in Iselin, New Jersey. The conference will bring together over 85 key decision makers from leading biotechnology and pharmaceutical companies to discuss developments in pre-filled syringes and injection devices over the course of two days of presentations, panel discussions, and workshops. Attendees will have the opportunity to network with industry leaders, evaluate solutions from exhibitors, and return to their businesses with the information and contacts needed to make decisions for their products.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, services, processes or ideas that are novel to an organization. Innovation can take various forms, including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
The document describes a team developing a technology to stabilize stem cells at room temperature, removing the need for freezing. The team includes Dr. Joanne Hackett, founder and CSO, with experience in regenerative medicine and business development, and Dr. Ryan MacDonald, project manager with a background in stem cell biology. The £100,000 investment would be used to protect intellectual property, undertake further studies, and provide seed funding to secure licensing deals and grants to further develop the technology.
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
Aqua Partners LLC is a global life science consulting firm that has been operating since 1983. They help life science companies access technology, products, partnerships, and capital worldwide. Their team of professionals have expertise in areas such as M&A, strategic partnerships, licensing, clinical development, and venture investing. Aqua Partners provides strategic advisory, valuation, business development, market research, and M&A services to clients in the life science industry globally.
Pitches from the 10 finalist teams selected to compete for the £100,000 Grand Prize of the inaugural OneStart competition in 2013, hosted by the Oxbridge Biotech Roundtable and SR One.
Learn more about this year's competition: http://oxbridgebiotech.com/onestart
SMi Group's 6th annual Pre-Filled Syringes conference & exhibition is already Europe's leading event. This year it will be better than ever. Check out the programme.
5th Annual Pre-Filled Syringes East CoastTeri Arri
This document provides an agenda for the Pre-Filled Syringes East Coast conference taking place on April 10-12, 2018 in Boston. The agenda includes workshops on human factors for connected drug delivery systems and design considerations for drug delivery outside the clinic on April 10th. The main conference on April 11-12th will feature sessions on regulatory updates, manufacturing challenges and solutions, trends toward biologics, and human factors considerations. Speakers will address topics such as syringe filling of high concentration formulations, safety evaluation of leachables, quality by design principles, and the future of digital monitoring biomarkers.
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
SMi Group's Prefilled Syringes East Coast 2018 conferenceDale Butler
This document summarizes a two-day conference on pre-filled syringes taking place in Boston on April 10-11, 2018. The conference will include two pre-conference workshops on human factors for connected drug delivery systems and design considerations for drug delivery outside the clinic. The main conference will focus on challenges and solutions for PFS manufacturing and processes, integrating quality by design principles, and trends toward increasing biologics and their implications for PFS. It will feature speakers from major pharmaceutical companies and include panel discussions on challenges of biologics delivery and PFS development.
Classified environments for aseptic manufacturing of sterile drug subtances and drug products require strict control to minimize the potential for microbiological and particulate contamination of the product. A well-designed environmental monitoring (EM) program is important to evaluate environmental controls in classified environments.
1 z fei portfolio r&d short resume cv and short support 2015inscore
This document is a curriculum vitae for Frank E. Inscore, summarizing his professional qualifications and experience. It highlights that he has over 15 years of experience in research and development leadership and management, including directing multi-functional teams toward materials characterization and analysis. He has successfully led numerous projects on time and under budget, generating over $15 million in revenue. His expertise includes spectroscopy, materials synthesis, and establishing effective cross-functional relationships to facilitate new product development.
LiquiLume Diagnostics develops molecular diagnostic devices that can detect individual molecules rapidly and inexpensively. Their initial focus is on nucleic acid testing (NAT) and protein biomarkers. They plan to first sell to research laboratories for research use only, then pursue FDA clearance to sell to clinical labs and hospitals. Their technology allows highly automated sample processing and analysis at low concentrations and low cost compared to standard methods.
Established in 2007, QFAB focuses on delivering robust, high quality and relevant bioinformatics services for life science researchers to analyse and manage large-scale datasets.
Our support ranges from experimental design, data capture and mining through to NGS, proteomic and metabolomic analyses. We are also expert in cross-domain integration with clinical data.
QFAB can work on specific projects, provide time against an ongoing need or become embedded in your organisation. Flexible, rapid and researcher oriented, QFAB has built a reputation for supporting the production of high quality outcomes which deliver those high impact publications or patents faster.
www.qfab.org
This document provides information about an upcoming conference on peptides to be held June 30 - July 2, 2014 in London. It will focus on peptide formulation, delivery, characterization, and development of new peptide drugs. The conference will feature keynote speakers from pharmaceutical companies discussing topics such as oral delivery of peptides and peptide drug manufacturing. An interactive workshop on extending peptide half-life will also be held. The event is aimed at strengthening knowledge of peptide therapeutic development and assessment.
1. Collaboration and data sharing in science is essential but requires technological and cultural changes to allow for analysis and insights.
2. Improving data sharing across organizations is challenging due to heterogeneous systems and social barriers.
3. The Medicines Discovery Catapult is supporting the biopharma sector by developing solutions to improve data interpretation, collaborative data sharing between organizations, and by matching industry challenges to technology providers.
The document describes TSRL Inc.'s Technology Accelerator program, which aims to help move therapeutic assets past the "Valley of Death" by providing infrastructure, scientific and business resources, and funding to drive projects from pre-clinical development to an Investigational New Drug application. The accelerator selects potential drug candidates based on criteria to maximize commercialization potential and provides services like project management, drug development expertise, and access to networks to help obtain funding and partners. The goal is to generate necessary data packages and commercialization plans to support projects reaching their next development milestones.
This document provides information about the "Pre-Filled Syringes Americas" conference taking place from March 31 - April 2, 2014 in Iselin, New Jersey. The conference will focus on the development, manufacture, and regulation of pre-filled syringe and injector devices in the Americas region. It will include presentations and panels from industry experts, as well as an exhibition and networking opportunities. Attendees will learn about topics like developing delivery systems for biologics, managing extractables and leachables, and gaining FDA approval. A half-day post-conference workshop on April 2nd will provide insight on accelerating regulatory approval of combination products.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
This document provides information about the "Cell Based Assays Americas" conference to be held on July 19-20, 2012 in Boston, USA. The conference will focus on advances in cell-based assays for drug discovery, development and toxicity testing. It will explore new techniques and applications of cell-based assays, including their use in reducing costs and risks in the drug development process. Speakers will discuss topics like high content screening strategies, 3D tissue models, stem cell technologies and interpreting results from cell-based assays. The agenda provides details of presentations on developing cell-based assay platforms and applications in areas like neurodegeneration, cardiotoxicity screening and kinase inhibitor mechanisms of action. The conference aims to highlight future growth opportunities in
Este documento es un conocimiento de embarque (AWB) que detalla el envío de maquinaria y equipos de procesamiento de datos desde Alemania a Colombia. El AWB incluye información sobre el expedidor, destinatario, aerolínea emisora, aeropuertos de origen y destino, peso y descripción de la mercancía, tarifas de flete y cargos aplicables.
Este documento es un conocimiento de embarque que proporciona información sobre una carga que está siendo transportada. Incluye detalles como el nombre y la dirección del embarcador y el consignatario, los puertos de carga y descarga, la descripción de los paquetes y la mercancía, y el peso bruto de la carga. El conocimiento de embarque es un documento legal importante que especifica los términos del transporte de la carga.
Este documento es un conocimiento de embarque que detalla el envío de maquinaria automática y lectores magnéticos desde Alemania a Colombia. El envío incluye 1 pieza que pesa 2,800 kg y el costo total del envío es de $11,163.03 USD.
5th Annual Pre-Filled Syringes East CoastTeri Arri
This document provides an agenda for the Pre-Filled Syringes East Coast conference taking place on April 10-12, 2018 in Boston. The agenda includes workshops on human factors for connected drug delivery systems and design considerations for drug delivery outside the clinic on April 10th. The main conference on April 11-12th will feature sessions on regulatory updates, manufacturing challenges and solutions, trends toward biologics, and human factors considerations. Speakers will address topics such as syringe filling of high concentration formulations, safety evaluation of leachables, quality by design principles, and the future of digital monitoring biomarkers.
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
SMi Group's Prefilled Syringes East Coast 2018 conferenceDale Butler
This document summarizes a two-day conference on pre-filled syringes taking place in Boston on April 10-11, 2018. The conference will include two pre-conference workshops on human factors for connected drug delivery systems and design considerations for drug delivery outside the clinic. The main conference will focus on challenges and solutions for PFS manufacturing and processes, integrating quality by design principles, and trends toward increasing biologics and their implications for PFS. It will feature speakers from major pharmaceutical companies and include panel discussions on challenges of biologics delivery and PFS development.
Classified environments for aseptic manufacturing of sterile drug subtances and drug products require strict control to minimize the potential for microbiological and particulate contamination of the product. A well-designed environmental monitoring (EM) program is important to evaluate environmental controls in classified environments.
1 z fei portfolio r&d short resume cv and short support 2015inscore
This document is a curriculum vitae for Frank E. Inscore, summarizing his professional qualifications and experience. It highlights that he has over 15 years of experience in research and development leadership and management, including directing multi-functional teams toward materials characterization and analysis. He has successfully led numerous projects on time and under budget, generating over $15 million in revenue. His expertise includes spectroscopy, materials synthesis, and establishing effective cross-functional relationships to facilitate new product development.
LiquiLume Diagnostics develops molecular diagnostic devices that can detect individual molecules rapidly and inexpensively. Their initial focus is on nucleic acid testing (NAT) and protein biomarkers. They plan to first sell to research laboratories for research use only, then pursue FDA clearance to sell to clinical labs and hospitals. Their technology allows highly automated sample processing and analysis at low concentrations and low cost compared to standard methods.
Established in 2007, QFAB focuses on delivering robust, high quality and relevant bioinformatics services for life science researchers to analyse and manage large-scale datasets.
Our support ranges from experimental design, data capture and mining through to NGS, proteomic and metabolomic analyses. We are also expert in cross-domain integration with clinical data.
QFAB can work on specific projects, provide time against an ongoing need or become embedded in your organisation. Flexible, rapid and researcher oriented, QFAB has built a reputation for supporting the production of high quality outcomes which deliver those high impact publications or patents faster.
www.qfab.org
This document provides information about an upcoming conference on peptides to be held June 30 - July 2, 2014 in London. It will focus on peptide formulation, delivery, characterization, and development of new peptide drugs. The conference will feature keynote speakers from pharmaceutical companies discussing topics such as oral delivery of peptides and peptide drug manufacturing. An interactive workshop on extending peptide half-life will also be held. The event is aimed at strengthening knowledge of peptide therapeutic development and assessment.
1. Collaboration and data sharing in science is essential but requires technological and cultural changes to allow for analysis and insights.
2. Improving data sharing across organizations is challenging due to heterogeneous systems and social barriers.
3. The Medicines Discovery Catapult is supporting the biopharma sector by developing solutions to improve data interpretation, collaborative data sharing between organizations, and by matching industry challenges to technology providers.
The document describes TSRL Inc.'s Technology Accelerator program, which aims to help move therapeutic assets past the "Valley of Death" by providing infrastructure, scientific and business resources, and funding to drive projects from pre-clinical development to an Investigational New Drug application. The accelerator selects potential drug candidates based on criteria to maximize commercialization potential and provides services like project management, drug development expertise, and access to networks to help obtain funding and partners. The goal is to generate necessary data packages and commercialization plans to support projects reaching their next development milestones.
This document provides information about the "Pre-Filled Syringes Americas" conference taking place from March 31 - April 2, 2014 in Iselin, New Jersey. The conference will focus on the development, manufacture, and regulation of pre-filled syringe and injector devices in the Americas region. It will include presentations and panels from industry experts, as well as an exhibition and networking opportunities. Attendees will learn about topics like developing delivery systems for biologics, managing extractables and leachables, and gaining FDA approval. A half-day post-conference workshop on April 2nd will provide insight on accelerating regulatory approval of combination products.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
This document provides information about the "Cell Based Assays Americas" conference to be held on July 19-20, 2012 in Boston, USA. The conference will focus on advances in cell-based assays for drug discovery, development and toxicity testing. It will explore new techniques and applications of cell-based assays, including their use in reducing costs and risks in the drug development process. Speakers will discuss topics like high content screening strategies, 3D tissue models, stem cell technologies and interpreting results from cell-based assays. The agenda provides details of presentations on developing cell-based assay platforms and applications in areas like neurodegeneration, cardiotoxicity screening and kinase inhibitor mechanisms of action. The conference aims to highlight future growth opportunities in
Este documento es un conocimiento de embarque (AWB) que detalla el envío de maquinaria y equipos de procesamiento de datos desde Alemania a Colombia. El AWB incluye información sobre el expedidor, destinatario, aerolínea emisora, aeropuertos de origen y destino, peso y descripción de la mercancía, tarifas de flete y cargos aplicables.
Este documento es un conocimiento de embarque que proporciona información sobre una carga que está siendo transportada. Incluye detalles como el nombre y la dirección del embarcador y el consignatario, los puertos de carga y descarga, la descripción de los paquetes y la mercancía, y el peso bruto de la carga. El conocimiento de embarque es un documento legal importante que especifica los términos del transporte de la carga.
Este documento es un conocimiento de embarque que detalla el envío de maquinaria automática y lectores magnéticos desde Alemania a Colombia. El envío incluye 1 pieza que pesa 2,800 kg y el costo total del envío es de $11,163.03 USD.
This bill of landing summarizes the shipment of 500 laptops from Shenzhen, China to Cali, Colombia. The shipment includes 500 laptops in 6 pallets, with 80 laptops per pallet and 1 pallet with 20 laptops. The total gross weight is 1650 kg and volume is 10.2 cubic meters. The shipment will be loaded onto the CSCL LE HAVRE vessel in Shanghai, China and transported to Buenaventura, Colombia. Ocean freight for the shipment is USD 3,300 and the terms of the contract are governed by Hong Kong law.
EL AGENCIAMIENTO DE TRANSPORTE INTERNACIONAL DE CARGA Y SEGURO DE TRANSPORTE ...Sebastian Betancur
En el presente trabajo se pretende ilustrar y analizar cómo se realiza un completo agenciamiento para el transporte internacional de carga, para esto se tendrá en cuenta cuales son las obligaciones del transportista
This international air waybill document is for a loose shipment of live geoduck clams from Vancouver, Canada to Shanghai, China. The shipper is International Foods Ltd in Vancouver and the consignee is Shank Yuan Ltd in Shanghai. The shipment contains 5 geoduck clams packaged in a cooler and requires immediate pickup by the consignee upon arrival due to its highly perishable nature.
Este documento describe varios tipos de documentos generados dentro de una empresa, incluyendo cartas circulares para comunicar noticias de interés, oficios para comunicar disposiciones u órdenes, certificados para confirmar hechos, permisos, solicitudes, cartas de renuncia, actas, cartas comerciales, contratos, informes y memorandums.
Este documento presenta información sobre diferentes tipos de comprobantes de pago externos e internos de la contabilidad. Explica conceptos como la factura, boleta de venta y boleta de transporte aéreo de pasajeros, describiendo sus características, clasificación, importancia y requisitos.
Este documento resume varios tipos de documentos comerciales utilizados en las operaciones de compra y venta. Incluye cotizaciones, pedidos, remesas, órdenes de producción, notas de entrada y salida de almacén, facturas de venta y documentos equivalentes. Cada uno tiene un propósito específico como registrar negociaciones, solicitar productos, entregar mercancías, controlar producción y llevar inventario.
El documento describe los diferentes tipos de documentos contables y títulos valores, así como sus objetivos, clasificaciones y requisitos. Explica que los documentos contables permiten controlar las operaciones de una empresa y comprobar los asientos, mientras que los principales títulos valores son cheques, letras de cambio y pagarés, los cuales se utilizan en transacciones comerciales. También detalla los pasos y documentación necesaria para la elaboración e inscripción de títulos y valores en la bolsa de valores.
El documento resume la logística del transporte internacional. Explica que la distribución física internacional (DFI) es el proceso de situar un producto en el mercado internacional cumpliendo con los términos acordados. Describe las 10 etapas secuenciales del transporte internacional y los principales actores involucrados en la DFI. Resalta que el objetivo de la DFI es reducir los tiempos, costos y riesgos durante el trayecto de origen a destino.
The document provides a detailed history of insurance beginning in ancient times. It discusses how early forms of insurance emerged in China, Babylon, and Persia to help communities cope with risks like shipwrecks or famines. Formal insurance contracts first appeared in 14th century Genoa and later spread to London. The Great Fire of London in 1666 spurred the development of fire insurance. The first insurance company in the US was established in Charleston, South Carolina in 1732 to provide fire insurance. Regulation of the insurance industry began in the 19th century at the state level. The document then provides milestones in the evolution of insurance in India and the nationalization of the life and general insurance sectors in India in 1956 and
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
2nd Annual Oncology Asia
Date: 7 – 9 September 2015 | Sheraton Miyako, Tokyo, Japan
www.oncologyasia.com
The 2nd Annual Oncology Asia zeroes in on the latest cutting edge developments in oncology drug discovery and late phase strategies to get oncology drugs to market faster! Under the Drug Discovery track, this conference will discuss latest immune checkpoint inhibitor combinations, preclinical development trends, novel biomarkers and oncology drug development case studies in Asia. Under the late phase track, it will discuss pricing for success, global and regional commercialization case studies, healthcare policy updates and pricing for success.
Find out about the latest drug discovery trends along with latest strategies for global and regional commercialization at the ONLY senior industry gathering focused on advancing cutting edge oncology R&D and commercialization strategies for Asia in Tokyo, Japan!
This document outlines a presentation on innovative strategies to accelerate drug development. It discusses Pfizer's locations in the UK and facilities for research, manufacturing, and commercial operations. Predictive science approaches using advanced data and technologies are described to enable accelerated development from molecule to medicine. Continuous manufacturing platforms and modular facilities are presented as ways to improve efficiency.
Innovation and entrepreneurship in biotechnology an intl perspective - d. h...sanguru1977
This document provides an introduction to innovation and entrepreneurship in biotechnology. It defines innovation as new products, processes or ideas that are novel to a business. There are different types of innovation including technological versus non-technological, and product versus process innovation. The document scopes the focus of the book, which is on entrepreneurship and innovation processes that are important for new biotechnology firms. It emphasizes the importance of innovation and entrepreneurship for competitiveness in the biotechnology industry.
The document summarizes the 14th Annual PepTalk conference organized by Cambridge Healthtech Institute. The conference will be held from January 19-23, 2015 in San Diego, CA and will feature over 1,200 international participants from industry, academia and government. It will include 20 conferences, 13 short courses, 325 speaker presentations, 80 roundtable discussions, 100 exhibitors and 125 research posters on topics related to protein engineering, antibody therapeutics, formulation, production, analytics and purification. A keynote speech will be given by Dr. John Yates from The Scripps Research Institute on advances in proteomics. The conference provides numerous opportunities for education, innovation and networking in the protein science field.
PEGS Europe Protein & Antibody Engineering Summit 2014 AgendaNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
Biologics World Taiwan 2016 (email me at justin.dejesus@imapac.com) Justin Barin de Jesus
The ONLY biopharmaceutical
gathering in Taiwan
Emphasizes on new business collaborations, demonstrate state-of-the-art developments and to propel Taiwan's biotech firms onto the world stage.
The document discusses how True Open Innovation and Boston Strategics' global network can improve drug development efficiency and lower costs. It outlines challenges in the pharmaceutical industry like decreased productivity and increased costs. It then describes how Boston Strategics uses a virtualized model and worldwide expert network to assemble project teams that can progress drug candidates through development faster and at lower expense than traditional models. Examples are provided of projects demonstrating savings of time and money. The goal is to establish an open innovation platform to facilitate drug development collaborations globally.
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
How True Open Innovation TM and its global network can expand the opportunity for drug development by increasing efficiency and decreasing costs
Luca Rastelli, PhD
Boston Strategics Corporation
October, 2013
Oral Drug Formulation Innovations 2014Simon Curtis
The Oral Drug Formulation Innovations Summit will examine and showcase the industry's latest formulation and delivery technologies for enhancing solubility and maximizing bioavailability. Leading global formulation experts in both industry and academia will share unique strategies on how to effectively develop poorly soluble drugs into scientifically unique, compliant, patient-centric formulations. Additionally, innovative strategies to significantly reduce product development timelines will be shared, and the latest regulatory requirements will be discussed.
The document discusses exploiting medicinal chemistry knowledge to accelerate drug discovery projects through in silico drug design techniques. It provides an agenda for a presentation covering problem statements around long development times, sources for design ideas like literature and patents, techniques for 2D and 3D molecular design including QSAR and docking models, and examples of applying these methods to specific drug targets. The presentation aims to explain how to analyze data rigorously and refine compound designs to find drug candidates faster.
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
Brochure (1) 10th Annual World Stem Cells & Regenerative Medicine Congress Ma...John Redaelli
The Stem Cells 2015 conference will take place from 20-22 May in London, featuring keynote speakers from industry leaders, biotech roundtables, and panels from stem cell foundations. Over 500 meetings are expected among 50+ exhibitors and 60+ speakers discussing commercializing cell therapies and gaining market access. Topics will include innovations in regenerative medicine, manufacturing, and new clinical applications for conditions like diabetes and stroke.
SMi Group's Adaptive Designs in Clinical Trials conferenceDale Butler
This document summarizes an upcoming conference on adaptive designs in clinical trials taking place from April 20-21, 2015 in London. The conference will focus on topics such as Bayesian adaptive designs, subgroup selection in clinical trials, integrating real-world patient data into adaptive trials, and designing biomarker-driven multi-arm multi-stage cancer trials. Speakers will discuss challenges with adaptive designs and their use in different therapeutic areas like neurodegenerative diseases. Participants can also register for optional half-day workshops on April 22nd focusing on Bayesian clinical trial designs and navigating international regulatory landscapes for adaptive trials.
GenScript ProBio: The World's Leading Biotech Company GenScript ProBio
GenScript ProBio is the world's leading biotech company founded in 2002 in New Jersey USA. We started a business in gene synthesis and established integrated innovative biologics CDMO platforms As of now, provide various solutions based on gene synthesis technology including gene and cell therapy vectors, biologics development and lentivirus manufacturing. Our team and leaders have years of experience in global biopharma companies and are committed to providing professional regulatory support for CMC development of biological products. We have the confidence to provide strong support for your projects. Visit our website for more information
https://www.genscriptprobio.com/gct-one-stop-lentiviralvector.html
This document summarizes a conference on RNA therapeutics. The conference will cover:
- Learning about pre-clinical and clinical developments in antisense oligonucleotide delivery and designing multifunctional nanoparticle carriers.
- Gaining insight into optimizing mRNA therapeutics and delivery methods, and understanding industry hurdles to targeted delivery beyond the liver.
- Featuring speakers from companies like Isis Pharmaceuticals, BioNTech AG, and Rigontech GmbH discussing topics like targeted delivery of antisense oligonucleotides, RNA vaccines, and modulating gene expression with oligonucleotides.
- Including workshops on next generation aptamer-conjugated RNA delivery and optimizing
This document provides information about the "Biosimilars & Biobetters USA 2014" conference to be held on April 7-8, 2014 in Iselin, New Jersey. The conference will focus on regulatory issues, commercialization strategies, and product development for biosimilars and biobetters in the US market. It includes an agenda with speaker information, session topics, and registration details. There will also be two post-conference workshops on April 9th on differentiation strategies for generics and launching biosimilars. The document aims to provide attendees with up-to-date insights and networking opportunities in the biosimilars industry.
Similar to 8th Asia Tides Feb 2016, Kyoto, Japan (20)
Bills of Lading are the most important documents in world
trade, including shipping of every kind. Understanding the
commercial and legal considerations are vital to successful
shipping and transportation of cargoes. All players involved
with Bills of Lading, including shipowners, charterers, brokers, agents, lawyers and bankers need to have a firm grasp of the complexities involved in careful use of these essential documents.
This document advertises and provides information about an upcoming intensive three-day training course on advanced laytime and demurrage. The course will have a limited group size and early registration is encouraged to save on fees. It provides details on course content, learning outcomes, target attendees, discounts for groups and in-house training, testimonials from past delegates, and contact information.
Fundamentals of Real Estate Investment, Development and ManagementJune Tan
This course draws on global and regional examples and is designedto provide you with a full understanding of the commercial, legal,development and management aspects of commercial and residential real estate. In particular, aspects of property valuation, ROI, leasing, strategic development decisions and property management will be
addressed.
Delegates will gain a thorough understanding of the valuation process, as well as explore the principles behind financing a project. This will include a review of the different financial instruments, how they can be used and their effect on the o verall performance of real estate projects.
Real estate evaluation experience is not required, but an understanding of concepts such as present value will be helpful. Investors, lenders, borrowers, valuers, property developers, government agents involved in real estate regulation, and financial analysts will greatly benefit from
attending this course.
The course includes many practical simulation exercises, and case studies, delegates are requested to bring their laptops to the course to link theory with practical experience and reinforce understanding of the extensive material provided to take away from the course.
Introduction to Ship Design and Naval ArchitectureJune Tan
This 2 day course is intended to provide interested parties with an overview of the fundamentals of naval architecture, to help them develop a better understanding of the science of ship design, and therefore their influence on the design and operation of ships.
The course will consider key aspects in ship design, such as ship stability and hydrostatistics, hull structures, durability, powering and machinery requirements as well as expected resistances when operating in the marine environment. Finally, these key areas will be integrated together within the typical design process used to develop
the design of a ship.
Shipyard Management - Design, Planning & OperationsJune Tan
This 2 day course is designed to provide essential knowledge in shipyard management and the various operations taking place – ship design, shipbuilding, repairs & maintenance, conversion and retrofitting. This includes
the early ship design and contracting stage, following up to the post contract, ship construction and production up until project completion and handover phase. Prepared by an international leading specialist in marine technology
and construction, the material covered in the in the various course modules explains the different shipyard processes and operations involved in a clear and straightforward manner.
This document advertises and provides information about an upcoming two-day maritime law training course in Singapore. It outlines key details such as the dates, location, savings available for early or group registration, course objectives, target attendees, and instructor biography. The course aims to help participants gain a fundamental understanding of maritime law principles, contracts, liability regimes, and insurance.
Marine Cargo Masterclass - Insurance, Surveys and ClaimsJune Tan
This document advertises and provides information about the Marine Cargo Masterclass - Insurance, Surveys and Claims training course. It outlines the key topics to be covered in the two-day course including marine insurance, surveys, claims handling and more. Interested individuals can register for the course taking place in Hong Kong and Singapore in May 2014. Special group discounts are available for teams of 3 or more registering together.
This document provides information about an upcoming LNG Tanker Operations training course. The course will take place on May 19-20, 2014 at the Grand Copthorne Waterfront Hotel in Singapore. It will provide attendees with knowledge on LNG tanker operations, commercial arrangements, cargo handling procedures, safety practices, and regulations. Attendees can save up to 40% by registering a group of 3 or more delegates for the special group rate. [END SUMMARY]
The document advertises an intensive training course on fundamentals of offshore support vessels held on May 22-23, 2014 in Singapore. It provides information on registration, group discounts, key learning outcomes, target attendees, testimonials from past delegates, and details on the course director. Registering teams of 3 or more can take advantage of special group rates and the 4th attendee attends for free. Early booking also allows saving up to SGD400. The course aims to provide a comprehensive overview of the offshore support vessel market and operations.
Public Private Partnerships 29-30 April 2014, SingaporeJune Tan
Public Private Partnerships are being extensively implemented, in Asia and around the world. Given the diverse nature of projects involved, and the unique requirements of different Governments and industry sectors, there is no one size fits all approach.
This 2 day intensive course will focus on best practice
methodologies essential to taking PPP decisions, be it model selection, application, structuring, finance, bidding, partner selection or risk mitigation. Using a combination of lectures, group discussion and a range of case studies, our expert course director will take attendees through the critical success factors for PPP projects.
Scrubber systems are becoming an increasingly possible option for shipowners to consider for either new shipbuilding or retrofitting on their current fleet. This is because scrubber systems are capable of removing
undesired SOx from a vessel’s exhaust gas emission to comply with ECA emission requirements of not more than 0.1 % sulphur content. At the same time though, the use of scrubber systems has raised various key issues including its ease of implementation, the commercial feasibility and challenges faced in adopting this technology.
This 2 day course will provide a comprehensive review of key scrubber systems issues, commercial and technical considerations before adopting scrubbers and the impacts on daily shipping operations. The course focuses on three main areas: emissions regulation, economics, and installation. In each area, challenges and benefits will be discussed, and essential points of consideration will be reviewed. Investment decisions will be analyzed
thoroughly, to factor in associated costs, possible savings and to determine the ROI on using scrubbers. Ship owners, managers and shipbuilders will leave this course with a more complete understanding of challenges to and
solutions for this increasingly important technology.
This 2-day course will show how the fundamental principles which underpin laytime and demurrage can be
changed quite dramatically by the wording of contractual
terms whether relating to dry cargo or tankers.
The course includes practical examples of calculations by way of a Worked Example and Case Studies.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
PET CT beginners Guide covers some of the underrepresented topics in PET CTMiadAlsulami
This lecture briefly covers some of the underrepresented topics in Molecular imaging with cases , such as:
- Primary pleural tumors and pleural metastases.
- Distinguishing between MPM and Talc Pleurodesis.
- Urological tumors.
- The role of FDG PET in NET.
About this webinar: This talk will introduce what cancer rehabilitation is, where it fits into the cancer trajectory, and who can benefit from it. In addition, the current landscape of cancer rehabilitation in Canada will be discussed and the need for advocacy to increase access to this essential component of cancer care.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
Joker Wigs has been a one-stop-shop for hair products for over 26 years. We provide high-quality hair wigs, hair extensions, hair toppers, hair patch, and more for both men and women.
The best massage spa Ajman is Chandrima Spa Ajman, which was founded in 2023 and is exclusively for men 24 hours a day. As of right now, our parent firm has been providing massage services to over 50,000+ clients in Ajman for the past 10 years. It has about 8+ branches. This demonstrates that Chandrima Spa Ajman is among the most reasonably priced spas in Ajman and the ideal place to unwind and rejuvenate. We provide a wide range of Spa massage treatments, including Indian, Pakistani, Kerala, Malayali, and body-to-body massages. Numerous massage techniques are available, including deep tissue, Swedish, Thai, Russian, and hot stone massages. Our massage therapists produce genuinely unique treatments that generate a revitalized sense of inner serenely by fusing modern techniques, the cleanest natural substances, and traditional holistic therapists.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
8th Asia Tides Feb 2016, Kyoto, Japan
1. IBC’s 8th Annual
Register Early and Save Up to USD400! www.IBCLifeSciences.com/AsiaTIDES
February 24-26, 2016 • Westin Miyako Kyoto • Kyoto, Japan
The only event in Asia bringing global oligonucleotide and peptide leaders together to discuss
current strategies and trends to accelerate promising molecules from research to commercialization
世界中のオリゴヌクレオチドとペプチドのグローバルリーダー達が一堂に会するアジア唯一のイベン
トで、前途有望な分子の研究から商業化までを加速するために、現在の戦略と傾向を話し合います。
Duchenne Muscular Dystrophy
Once-Weekly Peptide: Semaglutide
Challenge to be a Global
Pharma Innovator
Exon-skipping Therapies
Constrained Peptides and
Peptide-Based Drug Design
Locked Nucleic Acids
Global Experts Help Accelerate Your Molecules to Market
Joji Nakayama
Daiichi Sankyo, Japan
Masafumi Matsuo, M.D., Ph.D.
Kobe Gakuin University, Japan
Keiichi Masuya, Ph.D.
PeptiDream Inc., Japan
Troels Koch, Ph.D.
Roche Innovation Center
Copenhagen, Denmark
Shin'ichiTakeda, M.D., Ph.D.
National Center of Neurology
and Psychiatry, Japan
Jesper Lau, Ph.D.
Novo Nordisk A/S, Denmark
Media Parters: Organized by:
n Optimize the drug-like properties of your molecule for accelerated approval
• Phase 2/3 case studies • Delivery/formulation • Conjugates • Novel discoveries
n Discover CMC techniques and analytical strategies for complex molecules
• Large & small scale • Cost reduction • Novel synthesis • Lifecycle management
n Reach new markets & find partners for your molecules, technologies and services
•Innovation & investment landscape • Regulatory perspectives • Networking dinner
2. Dear Colleagues:
AsiaTIDES is Asia-Pacific’s leading oligonucleotide and peptide
therapeutics event for discovery, clinical and CMC scientists to share
best practices and success factors to help you accelerate molecules
from research to commercialization. The international speaker faculty
represents companies from the US, Europe, Japan, Australia and APAC
and provides a comprehensive update on the global progress of
oligonucleotides and peptides in development, so you can benchmark
your own programs and find new ideas to improve the development
of your products.
In response to your requests, this year’s program includes more
preclinical and clinical case studies than ever before from industry
bellwether companies including:
• Isis Pharmaceuticals
• Alnylam
• Novo Nordisk
• Roche
• Daiichi Sankyo
• Polyphor
• Sarepta Therapeutics
• CanBas
• Dicerna
• PeptiDream
• Noxxon
• miRagen Therapeutics
• Zealand Pharma
• and many more….
I encourage you to register today and maximize the value of attending
AsiaTIDES in Kyoto by participating in these additional activities:
• Share and find new research in the poster sessions
• Evaluate new products and services in the exhibit hall
• Find collaborators during the networking breaks, lunches,
networking dinner and cocktails
• Take an extra day to explore the historic and beautiful city of Kyoto
Sincerely,
Michael P. Keenan
Project Manager and Producer
Your International AsiaTIDES Advisory Committee
Robert Hagopian, Director Business Development, PolyPeptide Laboratories, USA
Yusuke Kohno, Vice President, Jitsubo Co Limited, Japan
Shawn Lee, Ph.D., President and CEO, CPC Scientific, USA and China
Dong-ki Lee, Ph.D., Professor, Sungkyunkwan University and CEO Founder, OliX
Pharmaceuticals, Korea
Patrick Lu, Ph.D., Founder, President and CEO, Sirnaomics, Inc., USA
Michael McGinley, Manager, Core Products, Phenomenex, USA
Bruce Morimoto, Ph.D., Executive Director Applied Translational, Medicine, Drug
Development Services, Celerion, USA
El Djouhar Rekaï, Head of Peptide Products Operation, Lonza, Belgium
Hideaki Sato, General Manager, Technical Support and Marketing, GeneDesign, Inc.,
Japan
Osamu Sato, Executive Director, RD Planning Department, Daiichi Sankyo, Japan
Dmitry Samarsky, Ph.D., SVP, International Business and Technology Development,
RiboBio, China
G. Susan Srivatsa, Ph.D., President, ElixinPharma, USA
Daisuke Takahashi, Ph.D., Manager, Bio-functional Molecular Chemistry Group,
Research Institute for Bioscience Products Fine Chemicals, Ajinomoto Co., Inc.,
Japan
2 To Register, Call: (+65) 6508 2401 • Fax: (+65) 6508 2407 • E-mail: register@ibcasia.com.sg
Accelerate Your Oligo and Peptide Molecules to Market
Meet the People Behind the Products and Get
the AnswersYou Need
The AsiaTIDES Exhibit Hall will give you the opportunity to find the
technologies and services you need to accelerate research, discovery
efforts and clinical programs. Visit vendor booths to discuss new product
advancements, network with industry and academic researchers, engineers
and executives during scheduled luncheons and receptions, or spend time
at the popular and innovative Poster Sessions. See more details on page 7.
Call for Posters
Limited space is available for poster presentations at this event.
If you have new results/data on topics relevant to this conference, we
encourage you to submit a poster abstract for consideration.
To present a poster, complete the conference registration form and
submit poster title and one page poster abstract online at
www.IBCLifeSciences.com/AsiaTIDES by January 27, 2016.
See registration form for poster fees.
The Westin Miyako Kyoto
1 Awataguchi Kachocho, Higashiyama-ku, Kyoto 605-0052, Japan
Tel: +81-75-771-7111 • Fax: +81-75-751-2490
Website: http://www.miyakohotels.ne.jp/westinkyoto/english/index.html/
Special Room Rates for AsiaTIDES Attendees:
JPY 19440/JPY 21600 (Superior Single/Twin) •JPY 25960/JPY 28080 (Deluxe Single/Twin)
To book a room at the Westin Miyako Hotel at the special AsiaTIDES group rate, please
reserve your room by visiting the hotel section at www.IBCLifeSciences.com/AsiaTIDES
3. Main Conference • Concurrent Tracks Wednesday, February 24, 2016
Oligonucleotides in Preclinical and
Clinical Development
11:00 Chairman’s Remarks
Karsten Schmidt, Ph.D., Senior Scientist, Structural Biology, Isis Pharmaceuticals, USA
11:15 Stabilization and Activation of Double-stranded Nucleic
Acid Drugs by Artificial Cationic Molecules
We have developed novel cationic oligosaccharides and cationic peptides that
selectively bind to A-type RNA/RNA and DNA/RNA duplexes. In this presentation,
I would like to describe the synthesis and properties of these unique molecules
as carriers and stabilizers of siRNA drugs and antisense DNA/RNA heteroduplexes.
Takeshi Wada, Ph.D., Professor, Department of Medicinal and Life Science,
Faculty of Pharmaceutical Sciences, Tokyo University of Science, Japan
11:45 Defining the Relationship between ASGR Binding and
Activity for GalNAc-ASO Conjugates
A fluorescence polarization competition assay was established to determine
the influence of GalNAc valency, ASO length, backbone composition and
charge on ASGR binding. Results gained from this approach were correlated
to ASO activity in hepatocytes and mice. Our work provides insights into the
interactions of ASO-conjugates with cell-surface receptors and on functional
uptake of ASOs into cells and tissues.
Karsten Schmidt, Ph.D., Senior Scientist, Structural Biology, Isis Pharmaceuticals, USA
12:15 Networking Luncheon with Exhibit and Poster Viewing
1:30 Presentation Sponsorship Opportunity
For more information about sponsoring a drug development case study,
application or technology presentation in this session, please contact
Patrick Gallagher at pgallagher@ibcusa.com.
2:00 PreclinicalTherapeutic Development againstTopical
Diseases Using Cell Penetrating, Asymmetric RNAiTriggers
Cell penetrating, asymmetric siRNA (cp-asiRNA) is an asymmetric RNAi trigger
with simple combination of chemical modifications. cp-asiRNA enters into cells
and triggers target gene silencing via RNA interference without the need of
delivery vehicle. Preclinical therapeutic development against skin, eye and lung
diseases using cp-asiRNA platform will be presented.
Dong-ki Lee, Ph.D., Professor, Sungkyunkwan University and Founder and
CEO, OliX Pharmaceuticals, Korea
Featured Presentation
2:30 Activity Determinants of Locked
Nucleic Acids
Small structural modifications of antisense oligonucleotides
can have significant effects on structure/activity relations. The
underlying nature of these subtle relationships cannot be
understood from a reductionist view point. We have employed
a new modelling strategy to get a better understanding on how
the structural units can impact the properties of LNA.
It will be presented how new chemical modifications and designs can improve
central therapeutic parameters of LNA.
Troels Koch, Ph.D., VP Head of Research, RNA Therapeutics,
Roche Innovation Center Copenhagen, Denmark
3:00 Networking Refreshment Break with Exhibit and Poster Viewing
Peptide Discovery
11:00 Chairman’s Remarks
Bruce Morimoto, Ph.D., Executive Director Applied Translational Medicine,
Drug Development Services, Celerion, USA
11:15 Oral Equivalents of Monoclonal Antibodies:
Exploitation of Constrained Peptides
This presentation will briefly describe platform technology and focus on
optimization of the oral delivery of constrained peptides, that are alternatives
to marketed antibodies Stelara and Entyvio, for treatment of IBD. The
presentation will describe rodent and monkey data, and criteria for selection
of IND candidates which should enter the clinic in 2015 and early 2016.
Mark Smythe, Ph.D., Founder and Vice President, Protagonist Therapeutics,
Australia
11:45 Presentation Title TBA
Abstract not available at time of print. Please visit
www.IBCLifeSciences.com/AsiaTIDES for updates.
Speaker TBA, Waters
12:15 Networking Luncheon with Exhibit and Poster Viewing
Drug Delivery Strategies for Peptides
1:30 Delivery Strategies for Peptides in Clinical Development
This presentation will include a brief overview of technologies available for
subcutaneous injection replacement, injectable sustained release formulation,
half-life extension and non-invasive delivery. The challenges and opportunities
for each of these approaches will be clarified. In addition, a pathway for clinical
development of a new peptide will be discussed along with strategy and
timing for incorporating life cycle options.
Christopher A. Rhodes, Ph.D., President and CEO, Drug Delivery Experts, USA
2:00 Peptide Mediated Delivery of Bioactive Proteins into Cells
Numerous approaches have been reported up to the present time for
intracellular delivery. However, approaches are still needed that have improved
efficacy in delivering high-molecular-weight proteins into cytosol to obtain
enhanced bioactivity. By modifying sequences of natural hemolytic peptides,
we have succeeded in creating a peptide, which has a low cytotoxicity but has
a high ability to yield a marked cytosolic release of endocytosed proteins.
Shiroh Futaki, Ph.D., Professor, Institute for Chemical Research,
Kyoto University, Japan
2:30 Biodegradable Silica Based Delivery of
Therapeutic Peptides
Biodegradable silica is a powerful drug delivery matrix for sustained release of
parenteral therapeutics. Encapsulation of peptides in nanoporous silica provides an
effective tool to administer peptides in a controlled manner even for several months.
The presentation describes the basics of silica technology with several case studies.
Lasse Leino, Ph.D., Adjunct Professor and CEO, DelSiTech Ltd., Finland
3:00 Networking Refreshment Break with Exhibit and Poster Viewing
Visit www.IBCLifeSciences.com/AsiaTIDES for up-to-date information on this event 3
Main Conference • Plenary Session Wednesday, February 24, 2016
Keynote Presentation
9:15 Therapeutic Approaches to Duchenne
Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is the most common
childhood genetic disease, affecting one in 3,500 newborn boys,
causing progressive muscle weakness, heart and respiratory
failure and premature death. This disease is caused by the
mutations of the DMD gene, and no cure exists for this disease, but a number
of promising new molecular therapies are being intensively studied. Among
them, exon skipping by antisense oligonucleotides is a novel method to
restore the reading frame of the mutated DMD gene, and rescue dystrophin
expression. I will present the recent progress of therapy of the disease.
Shin'ichi Takeda, M.D., Ph.D., Director General, National Institute of
Neuroscience, National Center of Neurology and Psychiatry, Japan
Keynote Presentation
9:45 Paradigm Shift in Drug Discovery:
Constrained Peptides and
Peptide-Based Drug Design
Constrained peptides represent highly valuable chemical
matter for use in biological validation, identifying hit/lead
molecules for drug discovery, and also directly as peptide
therapeutics. Our in-house approach to the optimization of constrained
peptides, and how these peptides contribute to hit finding for difficult target
classes from a general perspective will be introduced.
Keiichi Masuya, Ph.D., Chief Operating Officer, PeptiDream, Inc., Japan
8:15 Registration and Coffee
9:10 Chairman’s Remarks Paul Watt, Ph.D., Chief Scientific Officer, Phylogica Ltd, Australia
10:15 Networking Refreshment Break with Exhibit and Poster Viewing
4. Main Conference • Concurrent Tracks Wednesday, February 24, 2016(continued)
4 To Register, Call: (+65) 6508 2401 • Fax: (+65) 6508 2407 • E-mail: register@ibcasia.com.sg
3:45 Daiichi-Sankyo’s Strategies and Experiences in Biologics
focused Oligonucleotide Drug Development
This presentation will discuss Daiichi-Sankyo’s progress in the development of
biologics especially oligonucleotide drugs. Lessons learned to date, technical
challenges experienced and future approaches to progress our oligonucleotides
drugs as an important part of our biologics pipeline will be presented.
Junichi Koga, Ph.D., Corporate Officer and Global Head of Biologics,
Daiichi Sankyo, Japan
4:15 ALN-HBV, An Investigational RNAi Drug for the
Treatment of Chronic Hepatitis B
Chronic hepatitis B infection is a serious liver disease impacting 400 million
people worldwide. Clinical manifestations are severe, and an estimated 1
million people die each year from the disease and its complications. With
today’s medicines, the cure rate for chronic HBV infection is less than 10%.
An RNAi therapeutic inhibiting all steps of the HBV life cycle and silencing
tolerogenic viral antigens has the potential to achieve a“functional cure.”
Laura Sepp-Lorenzino, Ph.D., Vice President, Entrepreneur-in-Residence,
Alnylam Pharmaceuticals, USA
4:45 Eteplirsen a Drug for Duchenne Muscular Dystrophy
DMD, a neuromuscular disease, affects ~1:3500 of newborn boys and
invariably leads to their untimely death. DMD is most commonly caused
by deletions in the DMD gene that disrupt the mRNA reading frame and
prevent translation of dystrophin, an essential muscle protein. In ongoing
trials, eteplirsen, a morpholino oligomer, has been shown to restore the mRNA
reading frame and induce production of dystrophin. This treatment led to
significant benefit in the six-minute walk test.
Ryszard Kole, Ph.D., Distinguished Scientist, Sarepta Therapeutics, USA
3:45 Phylomer Derived Cell Penetrating Peptides Facilitate
More Efficient Delivery of Peptides and Proteins to
the Cytoplasm
Phylomer peptide libraries have been screened for new cell penetrating peptides
for delivery of macromolecules and nanoparticles into cells. A novel genetic
screen known as the‘endosome escape trap’enables the isolation of rare CPP’s
which more efficiently deliver their cargoes to the cytoplasm. Some of these
cell penetrating Phylomers can be targeted to particular cell types. Phylogica has
developed a variety of functional assays to determine the extent of cytoplasmic
delivery of peptide and protein cargoes to the cytoplasm or nucleus. These
assays have shown Phylomer CPP’s to be 37-160 times more efficient than
TAT which can be active in vivo. These tools are now being applied in screens
targeting transcription factor oncoproteins such as cMyc NMyc and STAT5 as well
as for more efficient intracellular delivery of protein toxin conjugates.
Paul Watt, Ph.D., Chief Scientific Officer, Phylogica Ltd, Australia
4:15 An Improved Transdermal Patch of Teriparatide Using
Ionic Liquid Transdermal System (ILTS)
Teriparatide is a recombinant parathyroid hormone used in the treatment
of osteoporosis and approved as a subcutaneous injection. A transdermal
patch which delivers teriparatide is being developed using Ionic Liquid
Technology. A series of in vitro rat skin permeation tests and in vivo rat PK
studies have been conducted which led to selection of a formulation which
demonstrated a temporary increase in the concentration of teriparatide in the
blood. Additionally, dermal irritation tests confirmed that there was no dermal
irritation to the rat skin.
Tatsuro Moriyoshi, Researcher, RD Department, MEDRx Co. Ltd., Japan
Panel Discussion
4:45 Drug Delivery Systems and Strategies
Moderator: Bruce Morimoto, Ph.D., Executive Director Applied Translational
Medicine, Drug Development Services, Celerion, USA
5:15 Networking Reception in Exhibit and Poster Hall Co-sponsored by: and
Main Conference • Plenary Session Thursday, February 25, 2016
8:30 Registration and Coffee
8:55 Chairman’s Remarks
William S. Marshall, Ph.D., President and CEO, miRagen Therapeutics, USA
The Innovation and Investment Landscape
in Japan and China
9:00 The Japan Landscape of Investment and Innovation in
Oligonucleotide and Peptide Development
INCJ is a public-private investment fund which provides financial and
management support for next-generation businesses including innovative
drug development. This presentation will provide an overview of the
investment and innovation landscape in Japan as well as discuss the
future potential of and opportunities in oligonucleotide and peptide drug
development in Japan.
Koichi Ashida, Executive Managing Director, Innovation Network of
Japan, Japan
9:30 Development and Production of Therapeutic
Oligonucleotides in China
There is a growing interest towards oligonucleotide-based therapeutics among
drug developers in China. The field, however, still remains at relatively early
stages. This presentation will summarize current status of oligonucleotide
therapeutic programs. It will also outline the situation with the oligonucleotide
manufacturing capabilities in China. Finally, a summary of the recently introduced
by CFDA changes to the overall drug development process and procedures in
the country will be presented.
Dmitry Samarsky, Ph.D., SVP, International Business and Technology
Development, RiboBio, China
Keynote Presentation
10:00 Exon-skipping Therapy Advancing
Oligonucleotide Drug Development
This presentation will describe continued efforts in our laboratory
to exploit exon-skipping oligonucleotides to treat a variety of
diseases. Current progress and ongoing challenges of exon-
skipping will be discussed. An update on the learnings from
clinical studies in DMD patients will also be presented.
Masafumi Matsuo, M.D., Ph.D., Professor, Department of Medical Rehabilitation,
Kobe Gakuin University, Japan
10:30 Networking Refreshment Break with Exhibit and Poster Viewing
Oligonucleotides in Preclinical and
Clinical Development (continued)
Drug Delivery Strategies for Peptides (continued)
6:45 Networking Dinner in Kyoto
Join fellow attendees in a fantastic networking and dining opportunity at a
local restaurant in beautiful Kyoto. Space is limited and an additional fee applies.
Please indicate when you register if you plan to join the dinner.
5. Visit www.IBCLifeSciences.com/AsiaTIDES for up-to-date information on this event 5
Main Conference • Concurrent Tracks Thursday, February 25, 2016(continued)
11:10 Chairperson’s Remarks
Sven Klussmann, Ph.D., Chief Scientific Officer, NOXXON Pharma AG,
Germany
11:15 Clinical Efficacy of AZD9150, a Next Generation,
Constrained Ethyl Modified Antisense Oligonucleotide
Inhibitor of STAT3 – Tumor Cell Autonomous and
Immuno-modulatory Activity
AZD9150 is a next generation ASO that has demonstrated robust single
agent efficacy in several tumor types in phase I clinical studies. Preclinical and
clinical data suggest the activity of AZD9150 is mediated by both tumor cell
autonomous effects as well as through modulation of the immunosuppressive
microenvironment through the inhibition of STAT3 in tumor-associated
immune cell populations.
A.Robert MacLeod, Ph.D., Vice President Oncology and Exploratory
Discovery, Isis Pharmaceuticals, USA
11:45 Mirror-image Oligonucleotide Aptamers Inhibiting the
Chemokine CXCL12/SDF-1 - From Identification to Phase
IIa Data
SDF-1/CXCL12 is a pro-angiogenic chemokine that plays a major role in
homing processes of stem cells and malignant stem cells. Furthermore,
the chemokine also interacts with two receptors, i.e. CXCR4 and CXCR7.
We have identified a high affinity mirror-image oligonucleotide (NOX-A12,
olaptesed pegol) that neutralizes SDF-1's interactions with both receptors.
The compounds showed intriguing efficacy in different oncology models.
Currently, the substance is profiled in two Phase IIa studies in patients with
multiple myeloma and chronic lymphocytic leukemia.
Sven Klussmann, Ph.D., Chief Scientific Officer, NOXXON Pharma AG,
Germany
12:15 Networking Luncheon with Exhibit and Poster Viewing
1:30 DNA/RNA Heteroduplex Oligonucleotide as a Novel
Concept of Therapeutic Oligonucleotide
We develop a short DNA/RNA heteroduplex oligonucleotide (HDO) with a
structure different from double-stranded RNA used for short interfering RNA
and single-stranded DNA used for ASO. A DNA/lockednucleotide acid gapmer
duplex with an a-tocopherol-conjugated complementary RNA (Toc-HDO) is
significantly more potent at reducing the expression of the targeted mRNA in
liver compared with the parent single-stranded gapmer ASO. Toc-HDO also
improves the phenotype in disease models more effectively. In addition, the
high potency of Toc-HDO results in a reduction of liver dysfunction observed
in the parent ASO at a similar silencing effect.
Takanori Yokota, M.D., Ph.D., Professor, Neurology Neurological Science,
Tokyo Medical and Dental University, Japan
2:00 From Concept to Clinic: MRG-106, a
LNA-antimiR® Targeting microRNA-155 for
Hematological Malignancies
microRNA-155 is a product of the bic oncogene and its overexpression has
been implicated as a poor prognostic indicator in a variety of hematological
malignancies. We identified MRG-106 through a rational screening approach
demonstrating target engagement in human cancer cells in vitro via passive
cellular uptake. Additional preclinical studies revealed a favorable PK/PD and
safety profile for the candidate. Our translational development strategy is based
on early mechanistic proof of concept and progressive de-risking in man.
William S. Marshall, Ph.D., President and CEO, miRagen Therapeutics, USA
2:30 Oligonucleotides in Oncology and Conjugation Strategies
Abstract not available at time of print. Please visit
www.IBCLifeSciences.com/AsiaTIDES for updates.
Bob Brown, Ph.D., CSO and SVP, Research, Dicerna Pharmaceuticals, USA
3:00 Networking Refreshment Break with Exhibit and Poster Viewing
11:10 Chairperson’s Remarks
El Djouhar Rekaï, Head of Peptide Products Operation, Lonza, Belgium
11:15 Cystine Knot Peptides asTemplates in Drug Design
Cyclotides are ultra-stable cystine-knot containing peptides that have great
potential as templates in drug design. There are now 15 published examples
of cyclotide-based drug leads for conditions including cancer, cardiovascular
disease, autoimmune disease and pain, amongst others. This presentation will
describe the design strategies and future possibilities for cyclotide-based drug
design. Of particular note is the ability of cyclotides to penetrate cells and
modulate intracellular targets, including protein-protein interactions.
David Craik, Ph.D., Professor of Biomolecular Structure, Institute for
Molecular Bioscience University of Queensland, Australia
11:45 New Broad Activities of CBP501 in Tumor Cells and the
Tumor Microenvironment Uncovered by the Results of
Phase II Clinical Studies
CBP501, a synthetic dodecapeptide, completed two Phase II clinical studies
for malignant pleural mesothelioma and NSCLC. In the NSCLC study, survival
was significantly prolonged in a patient population with normal WBC. These
results led to studies revealing new broad effects of calmodulin modulation by
CBP501 in tumor cells and the tumor microenvironment. CBP501 continues to
hold promise as a drug candidate in the paradigm-shifted immune oncology
drug development world.
Takumi Kawabe, M.D., Ph.D., President CEO, CanBas Co. Ltd., Japan
12:15 Networking Luncheon with Exhibit and Poster Viewing
1:30 Macrocycles Addressing
ChallengingTherapeuticTargets –
An Underexploited Structural Class
Macrocycles provide diverse functionality and stereochemical complexity in a
conformationally pre-organized ring structure. This can result in high affinity
and selectivity for challenging intra- and extracellular protein targets while
preserving excellent bioavailability. Polyphor has developed two proprietary
technologies for the generation of fully synthetic macrocycles for target-
based as well as phenotypic screening. An automated and highly streamlined
medicinal chemistry optimization process to advance initial hits to clinical
candidates in rapid iterative cycles is in place. This presentation will focus on
some representative case studies.
Daniel Obrecht, Ph.D., Chief Scientific Officer, Co-Founder, Polyphor Ltd.,
Switzerland
2:00 Presentation Sponsorship Opportunity
For more information about sponsoring a drug development case study,
application or technology presentation in this session, please contact
Patrick Gallagher at pgallagher@ibcusa.com
Peptide CMC and Analytical Strategies
2:30 Improved Chemical and Physical Stability in Liquid
Formulations – How to Design Stable Glucagon Analogues
Through a series of iterative changes in the native sequence of glucagon
we present an optimized glucagon analogue (ZP-GA-1) suitable for
long term storage as a liquid formulation with a pharmacokinetic and
pharmacodynamic profile of native glucagon. ZP-GA-1 exhibits superior
solubility (25 mg/ml) at neutral pH relative to native glucagon and
improved chemical and physical stability.
Lise Giehm, Ph.D., Senior Scientist, Pharmaceutical Development,
Zealand Pharma A/S, Denmark
3:00 Networking Refreshment Break with Exhibit and Poster Viewing
3:30 CMC Challenges and Large Scale
Manufacturing of Synthetic Peptides
The latest developments in the large scale manufacturing of synthetic
peptides will be presented. The talk will consider CMC challenges, process
development and manufacturing aspects for large scale SPPS and prep.
HPLC purification.
Daniel Samson, Ph.D., Senior Director API Manufacturing, Bachem AG,
Switzerland
Oligonucleotides in Preclinical and
Clinical Development (continued)
Peptide Discovery, Preclinical and Clinical
6. Main Conference • Plenary Session Friday, February 26, 2016
6 To Register, Call: (+65) 6508 2401 • Fax: (+65) 6508 2407 • E-mail: register@ibcasia.com.sg
8:45 Registration and Coffee
9:10 Chairman’s Remarks
Osamu Sato, Executive Director, RD Planning Department, Daiichi Sankyo,
Japan
Keynote Presentation
9:15 Challenge of Daiichi-Sankyo to be a Global
Pharma Innovator: Updated Directions
This presentation will discuss the challenge of Daiichi-
Sankyo to become one of the world’s leading innovators in
pharmaceutical drug business and RD with a diverse drug
portfolio. This talk will give an overview of Daiichi-Sankyo's
strategic business and scientific strategies, including its vision in the field of
oligonucleotide drug development.
Joji Nakayama, Representative Director, President CEO, Daiichi Sankyo,
Japan
Featured Presentation
9:45 Semaglutide, An Acylated GLP-1 Analog
Suitable for Once-Weekly Administration
Following the successful development of the first once-daily
GLP-1 analog liraglutide, we aimed to discover analogs suitable for
once-weekly dosing through acylation with fatty acids enabling
binding to serum albumin in vivo.This technology avoids the need
for substantially increased molecular weight by fusion to a large inactive protein,
or marked additives in the formulation requiring larger needle sizes.The fatty acid
“sidechain”was one of the key features to secure the combination of high albumin
affinity and high GLP-1R potency. Several parameters were investigated such as
length and type of fatty acid as well as the linking chemistry between the fatty acid
and GLP-1. Semaglutide has a peptide backbone with two substitutions compared to
human GLP-1 (8Aib, 34Arg) and is derivatized with a fatty acid“sidechain”at lysine 26.
Semaglutide is in phase 3 clinical trial for treatment of diabetes.
Jesper Lau, Ph.D., Vice President, Diabetes Protein and Peptide Chemistry,
Novo Nordisk A/S, Denmark
10:15 Refreshment Break
10:45 Late Breaking Presentation
Regulatory Perspectives on Oligonucleotide
and Peptide Impurities
11:15 Regulatory Considerations and Challenges on Impurity
Issues during Different Phases of Oligonucleotide and
Peptide Drug Development
Due to their diverse therapeutic activities, peptides and oligonucleotides may
be regulated under different regulations in the US, for example, as chemical
drugs or biological products, with different requirements for each. ICH changes
to the peptide guidance have also made it very challenging for companies to
deal with regulatory issues such as impurities, during the different phases of
development. The presentation will discuss 1) the effects of organization and
process changes in the US on the review and approvals of oligonucleotide and
peptide products, 2) the unique regulatory issues associated with impurities of
oligonucleotides and peptides and 3) common mistakes and how to manage
potential impurity problems during different phases of drug development, for
example, during site scale-up and site changes.
Duu-Gong Wu, Ph.D., Director/Senior Consultant, PPD Regulatory
Consulting and Former Deputy Division Director, Division of New Drug
Chemistry, US FDA/CDER, USA
11:45 Close of AsiaTIDES Main Conference
Main Conference • Concurrent Tracks Thursday, February 25, 2016(continued)
Oligonucleotide CMC and Analytical Strategies
3:30 CMC Case Study
Abstract not available at time of print. Please visit
www.IBCLifeSciences.com/AsiaTIDES for updates.
Alun Garner, Business Development Manager, Nucleic Acid Solutions
Division, Agilent Technologies, Inc.
4:00 Small Scale Manufacturing of Novel Oligonucleotides
Abstract not available at time of print. Please visit
www.IBCLifeSciences.com/AsiaTIDES for updates.
Huihe (Julia) Zhu, Ph.D., Group Leader, Small Scale Oligo Unit,
Nitto Denko Avecia
4:30 GalNac Conjugated LNA Oligonucleotides
This presentation will describe our progress with GalNac conjugated LNA
oligonucleotides. The focus of the presentation will be on CMC studies and
lessons learned, with some in-vivo data also presented.
Christoph Rosenbohm, Ph.D., Senior Director Research Operations,
Roche Innovation Center Copenhagen, Denmark
5:00 Close of Day Two
4:00 Life-cycle Management in Peptide Manufacturing
As technologies for the production of synthetic peptides evolve, the
chemical processes developed and validated 15 or 20 years ago often need
to be optimized for safety, productivity and cost effectiveness. As a leader in
the custom manufacturing of synthetic peptides, Lonza is putting emphasis
on the life-cycle management of its products in an increasingly competitive
environment. This case study of a generic peptide will present the activities
involved to support such a program, including process and analytical
development, process qualification and validation as well as the regulatory
filing strategy. The benefits of such a program will be described, both for the
CMO and for the customer.
Jean-Marc Poudrel, Ph.D., Program Manager, Lonza Braine SA, Belgium
4:30 Development of a Large Scale Process
for the Manufacture of a Small Cyclic
Peptide API
Abstract not available at time of print. Please visit
www.IBCLifeSciences.com/AsiaTIDES for updates.
Jon Holbech Rasmussen, Ph.D., Director Global Development,
PolyPeptide Group, Sweden
5:00 Close of Day Two
Peptide CMC and Analytical Strategies (continued)
Conference Language
The conference will be conducted in English without translation.
Travel/Visa Information
PLEASE NOTE: Visas are required for some nationalities to travel to Japan for this conference. Please
contact your travel agent and/or the Japanese Consulate/Embassy in your country for exact details
and visa application procedures as soon as possible. Visa processing times can vary.
About the Organizers
This event is brought to you by the organizers of the TIDES and EuroTIDES conferences. IBC
Life Sciences, an Informa business, is your connection to the life sciences industry. To see all
of the in-depth content IBC Life Sciences has to offer, visit www.IBCLifeSciences.com.
“AsiaTIDES was extremely productive. The senior players who attended and the intimacy of the conference afforded
many opportunities for networking with current and potential collaborators. It's a great forum if you want to further your
scientific knowledge and meet new partners. – Peter Lutwyche, Ph.D., Arbutus Biopharma Corporation
7. Sponsors and Exhibitors(As of October 2, 2015 , 2015)
Visit www.IBCLifeSciences.com/AsiaTIDES for up-to-date information on this event 7
Post-Conference Workshops Friday, February 26, 2016 • 12:00pm-4:00pm
Workshop #1: Current Status of Oligonucleotide
Drug Delivery Approaches and Systems (DDS)
Workshop Moderator: Dmitry Samarsky, Ph.D., SVP, International Business and
Technology Development, RiboBio, China
RNAi and antisense oligonucleotides promise to become the third major therapeutic
modality (besides small molecules and biologics), offering an opportunity to target
virtually any disease causing gene. Such promise, however, requires addressing the
challenge of delivering oligonucleotide-based therapeutic compounds to the tissues/
organs originating the disorders, as well as inside the cells producing the disease
phenotype. This workshop will dissect the delivery issue into smaller sub-challenges,
review those in deeper detail and offer some examples of successful solutions
Additional topics to be discussed include:
•Why oligos bio-distribute predominantly to a small group of organs (mostly liver)?
• If endothelial barriers prevent from broader bio-distribution, what can be done about it?
• Is tissue/organ penetration an additional challenge/barrier for oligo drug delivery?
• How do oligonucleotides cross cellular membrane barriers?
• Should we consider oligos as a class or individual compounds when it comes
to delivery?
• How big of a factor for choosing delivery approaches is the manufacturing component?
Workshop #2: Peptide Formulations:
Regulatory Considerations for Early Clinical Research
Workshop Moderators:
Christopher A. Rhodes, Ph.D., President and CEO, Drug Delivery Experts
Bruce Morimoto, Ph.D., Executive Director Applied Translational Medicine,
Drug Development Services, Celerion
This workshop will discuss lifecycle strategies for peptides and peptide formulations
from late stage research to early clinical development and beyond. Formulation
challenges of novel and complex peptide structures will be presented along with
dosage form strategies in early stage development and techniques for lifecycle
planning. The workshop will include a detailed case study on buccal delivery of
peptides with an emphasis on the early stage strategies needed to establish feasibility
of the project. Additional peptide case studies from early to late stage development
along with challenges encountered and lessons learned will also be presented.
Additional topics to be discussed include:
• What goes into a US Investigational New Drug (IND) application?
• What research or formulation development work is needed?
• What toxicology work is needed?
• Simple versus complex formulations and delivery options and life-cycle management
12:00 Networking Luncheon for Workshop Attendees
1:00 Workshop Opening Remarks
2:30 Refreshment Break
4:00 Close of Workshop
Post-Conference
Workshop Schedule
Silver Sponsors
Agilent’s Nucleic Acid Solutions Division offers industry
leading experience to efficiently advance your lead oligo
candidates from clinic to market with a common goal of
patient health and safety. With Agilent, you always have peace of mind by partnering with a
company that has the financial resources, stability and vision required for long-term success.
Contact us at: pdl-oulderinfo@agilent.com and find out why the world’s most revolutionary
biotech companies and their Big Pharma partners are choosing Agilent Technologies to
develop and commercialize their oligo APIs.
Bachem specializes in the manufacture of peptides and
complex small molecules as APIs as well as innovative
biochemicals for research purposes. We offer technical
consultancy, comprehensive regulatory affairs support, and dedicated project management
from drug development through commercial scale cGMP production. Headquartered in
Bubendorf, Switzerland with affiliates in Europe and the U.S.
Established in 1981, ChemGenes, an ISO9001 certified
company, has consistently provided the highest quality
Phosphoramidites and Solid Supports in the market and
continues to lead the industry in oligonucleotide reagent manufacturing. Our Massachusetts
facility is setup for Bulk Therapeutic Grade phosphoramidite production for GMP grade
oligonucleotide manufacturing. Additionally, ChemGenes carries the widest variety of
modified phosphoramidites and supports currently used in oligonucleotide synthesis
including Microarray Technology, Oligonucleotide Therapeutics, Oligonucleotide Based
Probes and other areas of Nucleic Acid research. ChemGenes remains devoted to providing
you with invaluable customer service and comprehensive technical support.
Lonza offers the life sciences market a full range of bioresearch
products, development services and manufacturing for active
ingredients. For 30 years we have been helping companies increase product quality, improve
production processes, navigate regulatory hurdles, lower costs, and get to market faster.
From early development to in-market supply, our complete development services,
industry-leading manufacturing processes, broad technology platform and lifecycle
management experience can help take your product to the next level. For flexible,
high-quality manufacturing, development services and products, we can help.
Driven by Excellence, Guided by Experience. When you partner with
Avecia, (www.Avecia.com) you will be working with the leading
oligonucleotide CMO. Avecia offers the most extensive process
validation experience in the oligo industry. As a member of the Nitto
Denko Corporation (www.nitto.com), Avecia is committed to the future of the
oligonucleotide market. We offer our customers oligo manufacturing capacity in two
separate facilities (MA and OH). Our Cincinnati facility also provides expanded pre-clinical
oligo services (OliGROW), as well as small molecule expertise and production. Our aim is to
leverage our wealth of experience, to ensure we exceed our customer’s expectations. Avecia
has the stability and vision required for the long-term success of your oligo program.
The PolyPeptide Group is a leading provider of proprietary
GMP, generic and non-GMP peptides and peptide
conjugates for the pharmaceutical, cosmetic, and biotech
industries as well as basic research. With 6 GMP facilities located across 3 continents, the
Group supports peptide projects at all scales from pre-clinical through to commercialization.
Bronze Sponsors
Polyphor is a Swiss Pharma company focusing on the discovery and
development of macrocycle drugs addressing high unmet medical
needs. These macrocycles represent a new drug class
complementary to the classical small molecules and large biopharmaceuticals. Polyphor`s
proprietary technologies are broadly applicable to a wide array of biological targets and disease
areas and already delivered a rich pipeline of pre-clinical and clinical drug candidates.
Waters Division creates business advantages for laboratory-
dependent organizations by delivering ultra performance liquid
chromatography (UPLC), high performance liquid
chromatography (HPLC), chromatography columns and chemistry products, mass spectrometry
systems, laboratory informatics solutions, and comprehensive service programs to enable
significant advancement in healthcare delivery, environmental management, food safety, and
water quality
GeneDesign specializes in contract development and
manufacturing of oligonucleotides therapeutics and
diagnostics from screening stage to commercial stage.
Session Sponsors
Networking Reception Co-Sponsors
Exhibitors(As of October 2, 2015)
Agilent Technologies Inc
Bachem AG
BCN Peptides S.A.
ChemGenes Corporation
GeneDesign Inc
Hongene Biotechnology Ltd
Kinovate Life Sciences Inc
Lonza
Nitto Avecia
Polypeptide Group
ST Pharm
Connect with 200+ Oligo and Peptide Decision Makers
Reserve Your Exhibit Booth or Sponsorship Today!
• Showcase your latest technology to our targeted audience of key decision-makers
• Build invaluable relationships and form new partnerships that give you a
competitive advantage in the US, Europe and Asia-Pacific
• Gain international exposure through our specialized marketing campaign
Call today to learn about the cost effective ways to drive lead generation and
network with key buyers, including: Turn Key Exhibit Booth Packages, Event
Partner Packages; Spotlight Session and Luncheon Briefing Sponsorships;
Custom Emails, and Meeting Space
For more information on how you can connect with these key
buyers, contact: Patrick Gallagher • Tel: 617-512-6656
Email: pgallagher@ibcusa.com
8. Payment
Payment must be received 10 business days prior to the event.
To take advantage of discounts with an expiry cut-off date,
registration and payment must be received by the cut-off date.
• Payments by USD bank draft or cheque should be made
in favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-06,
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by telegraphic transfer in USD must be made to:
IBC Asia (S) Pte Ltd
A/C No.: 260-457866-178 (USD)
The Hongkong and Shanghai Banking Corporation Limited,
21Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by Credit Card (AMEX, VISA or MASTERCARD)
Please provide your Card Number, Name of Cardholder, Expiry
Date and Signature and send it by fax to +65 6508 2407.
Important Note
Please quote the name of the delegate, event title and
invoice number on the advice when remitting payment.
Bank charges are to be deducted from participating
organisations’ own accounts. Please fax your payment
details (copy of remittance advice, cheque or draft to +65
6508 2407).
Attendance will only be permitted upon receipt of full
payment. Participants wishing to register at the door
are responsible to ensure all details are as published.
IBC assumes no further liability or obligation, beyond
the refund of the paid registration fee, in the event of
postponement or cancellation by IBC.
Registration Substitutions/Cancellations
Should you be unable to attend, a substitute delegate
is welcome at no extra charge. Cancellations must be
received in writing at least 10 business days before the start
of the event, to receive a refund less 10% processing fee
per registration.The company regrets that no refund will
be made available for cancellation notifications received
less than 10 business days before the event. IBC reserves
the right to cancel or alter the content and timing of the
program for reasons beyond its control and will NOT be
held accountable for any costs incurred by the participants.
Speakers are subject to change without prior notification.
Data Protection
The personal information entered during your registration/
order, or provided by you, will be held on a database and
may be shared with companies in the Informa Group in
the UK and internationally. Occasionally, your details may
be obtained from or shared with external companies
who wish to communicate with you offers related to
your business activities. If you do not wish your details
to be used for this purpose, please contact our Database
Department at Email: database@ibcasia.com.sg, Tel: +65
6508 2400 or Fax: +65 6508 2408.
Please tick: o I enclose my Cheque/Draft payable to IBC Asia (S) Pte Ltd
o I am paying by bank transfer (copy attached)
o Payment by Credit Card: o Amex o Visa o Mastercard
Credit Card Payments: The best way to pay by credit card is through our secure on-line registration process, simply log on to the
website at www.IBCLIfeSciences.com/AsiaTIDES and click “Register Now”. If you would prefer to pay over the phone please complete
the contact name and details and someone from our Customer Services Team will call within 24 hours to take payment. As we treat your
credit card information in the strictest confidence, please do not send payment details by email.
Credit Card Contact:______________________________________ Department:_________________________________________
Direct phone number:____________________________________ Email:________________________________________________
Name: Dr/Mr/Ms_______________________________________ E-Mail______________________________________________
Job Title____________________________________________ Mobile no____________________________________________
Department__________________________________________ Company____________________________________________
Address_____________________________________________ Post Code____________________________________________
Tel________________________________________________ Main Business/Activity____________________________________
Name Title of Approving Manager____________________________ Name Title of Training Manager_____________________________
Industry Rates SAVE USD400
by Nov. 20, 2015
SAVE USD300
by Dec. 18, 2015
SAVE USD200
by Jan. 15, 2016
SAVE USD100
by Feb. 5, 2016
Standard Rate
After Feb. 5, 2016
o Main Conference + Workshop* USD 1,899 USD 1,999 USD 2,099 USD 2,199 USD 2,299
o Main Conference Only USD 1,599 USD 1,699 USD 1,799 USD 1,899 USD 1,999
Group Rates (3+ from same company)
SAVE USD400
by Nov. 20, 2015
SAVE USD300
by Dec. 18, 2015
SAVE USD200
by Jan. 15, 2016
SAVE USD100
by Feb. 5, 2016
Standard Rate
After Feb. 5, 2016
o Main Conference + Workshop* USD 1,699 USD 1,799 USD 1,899 USD 1,999 USD 2,099
o Main Conference Only USD 1,399 USD 1,499 USD 1,599 USD 1,699 USD 1,799
*Select one Post-Conference Workshop:
o Workshop #1: Current Status of Oligonucleotide Drug Delivery Approaches and Systems (DDS)
o Workshop #2: Peptide Formulations: Regulatory Considerations for Early Clinical Research
Academia/Government Discounts – 40% Savings: Academic and government employees are eligible for over 40%
savings compared to the industry fees. Rate extended to full-time employees of government, universities and university-
affiliated hospitals who have NO affiliation to a for profit entity. See website for details.
Present a Poster o USD125 - Commercial o FREE - Academic
o Attend Networking Dinner (Tuesday, February 24, 2016 • 6:45pm) USD120
Please tell us your primary area of interest: o Oligonucleotides o Peptides
Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for
the same event, at the same time. Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early
bird rate OR special rate OR group rate. All fees stated include luncheons, refreshments and complete set of documentation. It
does not include the cost of accommodation and travel. Registration fees are subject to the prevailing government tax.
If undelivered, please return to:
111 Somerset Road
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: + 65 6508 2408
RESERVE YOUR PLACE TODAY!
This label contains your priority booking code. To expedite registration, please do not remove label. If you have already
received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not available to IBC
Asia (S) Pte Ltd for deduplication prior to mail drop.
SaveUpToUSD400
withtheEarlyBirdRates!
Groups of 3+ Save an
Additional USD200 per person.
See below for details!
AsiaTIDES – Oligonucleotide and Peptide® Research, Technology and Product Development
P46303
REGISTER NOW! FAX BACKTO (65) 6508 2407 OR EMAILTO REGISTER@IBCASIA.COM.SG
EASIEST: www.IBCLifeSciences.com/AsiaTIDES
CALL
+65 6508 2401
EMAIL
register@ibcasia.com.sg
5 WAYS TO REGISTER
FAX
+ 65 6508 2407
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road,
TripleOne Somerset #10-06,
Singapore 238164
MAILthe attached registration
form with your cheque to
Priority Code: R16225pdfwdl